Cargando…

Mechanisms of Resistance to Antibody-Drug Conjugates

The treatment of cancer patients has dramatically changed over the past decades with the advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and innovative T-cell therapy. Antibody-drug conjugates (ADCs) have also revolutionized the treatment of cancer. Several ADCs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khoury, Rita, Saleh, Khalil, Khalife, Nadine, Saleh, Mohamad, Chahine, Claude, Ibrahim, Rebecca, Lecesne, Axel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253543/ https://www.ncbi.nlm.nih.gov/pubmed/37298631 http://dx.doi.org/10.3390/ijms24119674

Ejemplares similares

LAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
por: Ibrahim, Rebecca, et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

New developments in the management of head and neck cancer – impact of pembrolizumab
por: Saleh, Khalil, et al.
Publicado: (2018)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
por: Esnault, Clara, et al.
Publicado: (2022)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

Repeated courses of low‐dose 2 × 2 Gy radiation therapy in patients with indolent B‐cell non‐Hodgkin lymphomas
por: Saleh, Khalil, et al.
Publicado: (2020)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response
por: Chang, Hannah L., et al.
Publicado: (2023)

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Antibody–Drug Conjugate Efficacy in Neuroblastoma: Role of Payload, Resistance Mechanisms, Target Density, and Antibody Internalization
por: Buongervino, Samantha, et al.
Publicado: (2021)

Recent Advances in Conjugated Polymers for Light Emitting Devices
por: AlSalhi, Mohamad Saleh, et al.
Publicado: (2011)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Exploration of the antibody–drug conjugate clinical landscape
por: Maecker, Heather, et al.
Publicado: (2023)

Antibody–drug conjugates: Recent advances in payloads
por: Wang, Zhijia, et al.
Publicado: (2023)

Methods for site-specific drug conjugation to antibodies
por: Behrens, Christopher R, et al.
Publicado: (2014)

Fate of Antibody-Drug Conjugates in Cancer Cells
por: Chalouni, Cécile, et al.
Publicado: (2018)

Factors Affecting the Pharmacology of Antibody–Drug Conjugates
por: Lucas, Andrew T., et al.
Publicado: (2018)

An overview of antibody–drug conjugates in oncological practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020)

Antibody-Drug Conjugates: The New Frontier of Chemotherapy
por: Ponziani, Sara, et al.
Publicado: (2020)

Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021)

Advances and Limitations of Antibody Drug Conjugates for Cancer
por: Mckertish, Candice Maria, et al.
Publicado: (2021)

Antibody–Drug Conjugates—A Tutorial Review
por: Baah, Stephanie, et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Toward Homogenous Antibody Drug Conjugates Using Enzyme-Based Conjugation Approaches
por: Hussain, Ahmad Fawzi, et al.
Publicado: (2021)

Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
por: Wu, Mo, et al.
Publicado: (2022)

Enzyme-Based Labeling Strategies for Antibody–Drug Conjugates and Antibody Mimetics
por: Falck, Georg, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ajg45p958tadqcdfcn02sa3qbl